Cargando…

Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system

BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Straßburg, Svenja, Linker, Carolin-Maria, Brato, Sebastian, Schöbel, Christoph, Taube, Christian, Götze, Jürgen, Stehling, Florian, Sutharsan, Sivagurunathan, Welsner, Matthias, Weinreich, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832687/
https://www.ncbi.nlm.nih.gov/pubmed/35148739
http://dx.doi.org/10.1186/s12890-022-01855-w
_version_ 1784648775319420928
author Straßburg, Svenja
Linker, Carolin-Maria
Brato, Sebastian
Schöbel, Christoph
Taube, Christian
Götze, Jürgen
Stehling, Florian
Sutharsan, Sivagurunathan
Welsner, Matthias
Weinreich, Gerhard
author_facet Straßburg, Svenja
Linker, Carolin-Maria
Brato, Sebastian
Schöbel, Christoph
Taube, Christian
Götze, Jürgen
Stehling, Florian
Sutharsan, Sivagurunathan
Welsner, Matthias
Weinreich, Gerhard
author_sort Straßburg, Svenja
collection PubMed
description BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF.
format Online
Article
Text
id pubmed-8832687
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88326872022-02-11 Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system Straßburg, Svenja Linker, Carolin-Maria Brato, Sebastian Schöbel, Christoph Taube, Christian Götze, Jürgen Stehling, Florian Sutharsan, Sivagurunathan Welsner, Matthias Weinreich, Gerhard BMC Pulm Med Research BACKGROUND: In this study we tested the hypothesis that in patients with cystic fibrosis (pwCF) respiratory rate (RR) is associated with antibiotic treatment, exacerbation status, forced expiratory volume in one second (FEV1) and C-reactive protein (CRP). METHODS: Between June 2018 and May 2019, we consecutively enrolled pwCF who were referred to our hospital. We determined RR and heart rate (HR) by using the minimal-impact system VitaLog during the hospital stay. Furthermore, we performed spirometry and evaluated CRP. RESULTS: We included 47 patients: 20 with pulmonary exacerbation and 27 without. RR decreased in patients with exacerbation (27.5/min (6.0/min) vs. 24.4/min (6.0/min), p = 0.004) and in patients with non-exacerbation (22.5/min (5.0/min) vs. 20.9/min (3.5/min), p = 0.024). Patients with exacerbation showed higher RR than patients with non-exacerbation both at the beginning (p = 0.004) and at the end of their hospital stay (p = 0.023). During the hospital stay, HR did not change in the total cohort (66.8/min (11.0/min) vs. 66.6/min (12.0/min), p = 0.440). Furthermore, we did not find significant differences between patients with exacerbation and patients with non-exacerbation (67.0/min (12.5/min) vs. 66.5/min (10.8/min), p = 0.658). We observed a correlation of ρ = -0.36 between RR and FEV1. Moreover, we found a correlation of ρ = 0.52 between RR and CRP. CONCLUSION: In pwCF requiring intravenous therapy, respiratory rate is higher at their hospital admittance and decreased by the time of discharge; it is also associated with C-reactive protein. Monitoring RR could provide important information about the overall clinical conditions of pwCF. BioMed Central 2022-02-11 /pmc/articles/PMC8832687/ /pubmed/35148739 http://dx.doi.org/10.1186/s12890-022-01855-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Straßburg, Svenja
Linker, Carolin-Maria
Brato, Sebastian
Schöbel, Christoph
Taube, Christian
Götze, Jürgen
Stehling, Florian
Sutharsan, Sivagurunathan
Welsner, Matthias
Weinreich, Gerhard
Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title_full Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title_fullStr Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title_full_unstemmed Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title_short Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
title_sort investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832687/
https://www.ncbi.nlm.nih.gov/pubmed/35148739
http://dx.doi.org/10.1186/s12890-022-01855-w
work_keys_str_mv AT straßburgsvenja investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT linkercarolinmaria investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT bratosebastian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT schobelchristoph investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT taubechristian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT gotzejurgen investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT stehlingflorian investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT sutharsansivagurunathan investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT welsnermatthias investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem
AT weinreichgerhard investigationofrespiratoryrateinpatientswithcysticfibrosisusingaminimalimpactbiomotionsystem